Our ambition : to find therapeutic solutions for pathologies associated with lymphatic vascular system failure for which no treatment is currently available.
We care for lymphedema
The lymphedema : an unmet medical need
The lymphatic system is a unidirectional vascular system that transports excess interstitial fluid into the bloodstream. A dysfunction of the lymphatic system causes an accumulation of lymph, leading to an edema known as lymphedema, which over time results in tissue changes: skin thickening and fat deposition. This condition is progressive and will gradually worsen through different stages.
The International Society of Lymphology (ISL) has defined several clinical stages, ranging from subclinical involvement (stage 0) to severe disabling deformity (elephantiasis):
Stage 1 : the edema is fluctuating, colorless, and pitting, reflecting the accumulation of water, rich in proteins;
Stage 2 : elevating the limb no longer reduces the volume of the edema. Skin problems begin to appear on the fingers or toes. The edema becomes firm, and the excess volume is less than 20% (stage 2A) or between 20% and 40% (stage 2B);
Stage 3 : the limb is large and difficult to move. Superficial lymphatic stasis leads to the appearance of trophic disorders, with hyperkeratosis and fibrosis. The excess volume is greater than 40%.
1st gene therapy for lymphedema
mRNA vector that enables the regeneration of the lymphatic system in the lymphedematous limb. A phase I/IIa clinical trial in patients who developed lymphedema after breast cancer will begin in 2025.
Use of Apeline and VEGFC for the treatment of lymphedema via a messenger RNA vector.
- Non Integrative
- Easy to produce
- Safer for cancer survivor patients
- In vivo delivery
Apernavec pipeline
The complementarity of experiences
Dr Julie Malloizel-Delaunay, MD.
CMO
Hospital MD, CHU Toulouse, head of the lymphology unit and competence center for lymphatic diseases.
Dr Barbara Garmy-Susini, PhD. CSO
Research Director Inserm (DR1) at I2MC Toulouse.
Coordinator of EU project H2020 Theralymph.
Vincent Nis
CEO
20 years’ experience
2005-2015 : chartered accountant and statutory auditor
since 2015 : CFO of several start-ups
Partners & Supports
Contact us
Patient ? Doctor ? Investor ?
Would you like to find out more about our scientific or entrepreneurial approach?
Send us an email with your contact details and we’ll get back to you as soon as possible.